MD Biosciences is an industry-leading provider of preclinical, translational and clinical-phase contract research services for the development of pharmaceutical and diagnostic assets. Established in 1991, MDB offers expertise, services and products across a wide range of therapeutic areas including inflammatory diseases, autoimmunity, neurology, oncology, metabolism, and pain. We collaborate with companies of all sizes, from small start-ups to large pharmaceutical pioneers, for the development of innovative therapeutics and diagnostic assays.
Our AAALAC-accredited and GLP-compliant preclinical facilities are state-of-the-art in technical capabilities for in vitro and in vivo studies, while our CLIA-certified diagnostic facilities support clinical investigations through fit-for-purpose assay design and validation. Our translational services bridge the gap between basic research findings and potential clinical utility, and include offerings such as application of unique biomarker signatures, selection or stratification of specific patient populations and mechanism of action determination. Additionally, we offer large-animal porcine models which demonstrate higher translatability of preclinical findings to the clinic, providing a more accurate representation of human anatomy and physiology.